Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Jumping Today

By Keith Speights - Updated May 14, 2020 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another COVID-19 test maker's pain appears to be behind Co-Diagnostics stock's gain.

What happened

Shares of Co-Diagnostics (CODX 4.47%) were jumping 16.4% higher as of 11:18 a.m. EDT on Thursday after rising as much as 26.9% earlier in the day. The big gain appears to be related in part to a New York University Langone Health study that identified possible inaccuracies with Abbott Labs' (ABT -0.41%) ID NOW diagnostics test for novel coronavirus disease COVID-19. Co-Diagnostics also markets a COVID-19 diagnostic test. 

So what

Bad news for Abbott Labs could be good news for Co-Diagnostics if it causes sales of the company's Logix Smart COVID-19 tests to rise. It remains to be seen if that's what happens, though.

Gloved hand holding a blood vial with a label showing a check mark in a box indicating positive for coronavirus

Image source: Getty Images.

The NYU study found that Abbott's ID NOW COVID-19 test missed one-third of samples that were identified as positive for COVID-19 by Danaher's Cepheid Xpert Xpress test. However, the study has not yet been peer-reviewed.

Abbott quickly responded to the NYU study, stating that the results from the study "are not consistent with other studies." The healthcare giant noted that another recent study found that ID NOW was highly accurate at detecting positive cases of COVID-19. 

But the NYU study is receiving a lot of publicity, especially since the White House is using Abbott's test for COVID-19 testing. This could give at least a temporary boost to Co-Diagnostics' sales of its own COVID-19 test.

Now what

We'll probably know fairly soon if the NYU study was flawed or truly identified issues with Abbott's ID NOW test. We'll also know even sooner how much the COVID-19 pandemic is helping Co-Diagnostics. The company reports its first-quarter results after the market closes today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$5.61 (4.47%) $0.24
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$108.65 (-0.41%) $0.45
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$253.52 (0.26%) $0.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.